【摘要】 目的探讨盐酸埃克替尼治疗非小细胞肺癌(NSCLC)的临床疗效。方法选择晚期NSCLC患者120例,采用随机数字表法将其分为研究组和对照组,每组60例。研究组患者口服盐酸埃克替尼,对照组患者给予多西他赛单药化疗,比较两组患者疗效,并对研究组不良反应发生情况进行统计。结果两组患者8周后近期有效率比较,差异无统计学意义(P﹥0.05),其余各时间段(治疗8周后、12周后、16周后)的疾病控制率及近期有效率研究组均高于对照组,差异均有统计学意义(P﹤0.05)。研究组15例患者发生皮疹,8例发生消化道反应,多为1~2级,无严重不良反应。结论对于治疗晚期NSCLC,盐酸埃克替尼有较好的临床疗效,并且安全性高,无严重不良反应发生,值得临床推广与应用。更多还原

【Abstract】 Objective To explore the curative effect of icotinib hydrochloride in non-small cell lung cancer(NSCLC)patients. Method 120 NSCLC patients were included in the study, and were randomized as study group and control group using a random number table, with 60 cases in each. Patients in study group were given oral icotinib, while the control group was treated with docetaxel monotherapy, and then the curative effects of the two groups were compared, and adverse reactions were statistically analyzed. Result The short-term response rate in 12-and 16-weeks, and the disease control rate in 8-, 12-, and 16-weeks after treatment were higher in study group compared with those in control group(P<0.05), though the short-term response rate in 8-weeks were similar between the two groups(P>0.05). There were 15 cases of rash, 8 cases of digestive tract reaction in study group, mostly at grade 1-2, with no serious adverse reactions observed.Conclusion For the treatment of advanced NSCLC, icotinib hydrochloride is clinically effective and safe, with little potential of inducing serious adverse reactions, which is worthy of clinical application.更多还原